| Contact, Use Central |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
| Completed | 3 | 262 | RoW | Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B) | Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd | Hyperkalemia, Renal Insufficiency, Chronic | 11/25 | 11/25 | | |
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone |
|
|
| Completed | 3 | 136 | US | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo | CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Graft Versus Host Disease (GVHD) | 09/23 | 06/24 | | |
| Terminated | 3 | 134 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 12/24 | 12/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Terminated | 3 | 16 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 06/25 | 07/25 | | |
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema |
|
|
| Completed | 3 | 22 | Europe, Canada, US, RoW | CSL312, Garadacimab | CSL Behring | Hereditary Angioedema (HAE) | 11/25 | 11/25 | | |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) |
|
|
| Recruiting | 3 | 35 | Canada, US, RoW | CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec | CSL Behring | Hemophilia B | 10/28 | 04/32 | | |
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
|
|
| Active, not recruiting | 2/3 | 222 | Europe, Japan, US, RoW | AAT, Alpha-1 proteinase inhibitor, Respreeza, Placebo | CSL Behring, Commercial/Industry, CSL | Acute-graft-versus-host Disease | 03/26 | 03/26 | | |
THRIVE-3, NCT06910943: Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support |
|
|
| Recruiting | 2/3 | 129 | Europe, US | Choline Chloride for Injection, Placebo | Protara Therapeutics | Choline Deficiency, Liver Injury | 06/27 | 06/28 | | |
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
|
|
| Recruiting | 2/3 | 2310 | Europe, Canada, Japan, US, RoW | CSL300, Clazakizumab, Placebo | CSL Behring | Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD | 08/29 | 08/29 | | |
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® |
|
|
| Completed | 2 | 81 | Europe, RoW | Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL | Astellas Pharma Europe Ltd. | Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation | 10/15 | 11/25 | | |
NCT06699849: Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis |
|
|
| Active, not recruiting | 2 | 70 | US, RoW | CSL889, Hemopexin, human, Placebo | CSL Behring | Sickle Cell Disease Vaso-occlusive Crisis | 08/27 | 08/27 | | |
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
|
|
| Recruiting | 2 | 38 | US | TARA-002 | Protara Therapeutics | Lymphatic Malformation | 12/25 | 05/26 | | |
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus |
|
|
| Recruiting | 2 | 18 | Europe, RoW | Difelikefalin | Vifor Fresenius Medical Care Renal Pharma | Pruritus, Chronic Kidney Diseases | 08/29 | 08/29 | | |
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 131 | Canada, Japan, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 05/30 | 08/30 | | |
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects |
|
|
| Terminated | 1 | 52 | Europe | CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo | CSL Behring | Immune Complex-mediated Autoimmune Diseases | 03/23 | 03/23 | | |
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge |
|
|
| Completed | 1 | 40 | Europe | CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo | CSL Behring | Healthy Volunteers | 07/23 | 07/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) |
|
|
| Completed | 1 | 10 | US | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 09/24 | | |
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
|
|
| Completed | 1 | 12 | Europe, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 10/24 | | |
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects |
|
|
| Completed | 1 | 62 | RoW | CSL040, Placebo | CSL Behring | Complement-mediated Disorders | 12/25 | 12/25 | | |
| Completed | N/A | 80 | Europe, US | | Protara Therapeutics | Intestinal Failure-associated Liver Disease | 06/23 | 06/23 | | |
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B |
|
|
| Recruiting | N/A | 500 | Europe, US | HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX) | CSL Behring | Hemophilia B | 08/43 | 08/43 | | |
